2025 Board of Directors Report
In 2025, the Board of Directors of Bluesail Medical Co., Ltd. (hereinafter referred to as the "Company" or "Bluesail Medical") strictly adhered to the "Company Law of the People's Republic of China" (hereinafter referred to as the "Company Law"), the "Articles of Association of Bluesail Medical Co., Ltd." (hereinafter referred to as the "Articles of Association"), and the "Rules of Procedure for Board Meetings" and other relevant regulations. The Board further standardized and optimized the Company's corporate governance structure, ensuring scientific decision-making and standardized operations. With the support of all shareholders, the Board led the management and all employees in actively responding to the complex operating environment and promoting the Company's sustained, stable, and healthy development. The following is a report on the Board of Directors' work in 2025:
I. Review of the Company's Operating Performance in 2025
2025 was a year of challenges and transformation, a year for Bluesail Medical to forge resilience amidst adjustment and deepen its focus to accumulate strength. It was a pivotal year in a decade of unremitting effort, resolute transformation, breaking through challenges, and embracing new beginnings. Looking back at the end of the "14th Five-Year Plan," this marked not only the end of a five-year plan but also a crucial juncture for Bluesail Medical's phoenix-like rebirth and strategic repositioning.
Based on the differing nature of its segmented businesses, the Company organized its business segments into the Cardiovascular and Cerebrovascular Business Unit, the Health Protection Business Unit, and the Emergency Care Business Unit. Its products cover the fields of cardiovascular and cerebrovascular, health protection, and emergency care, aiming to bring well-being to patients and create value for society with world-leading medical technologies and products.